newsfilter
← Latest News
GlobeNewswire·

Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026

70% in vivo editing of human APOC3 in a single administration76% triglyceride reduction after a single dose in murine disease model NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a genome